OncoMatch/Clinical Trials/NCT05961761
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
Is NCT05961761 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Propranolol and Pembrolizumab for soft tissue sarcoma adult.
Treatment: Propranolol · Pembrolizumab — The goal of this phase 2 clinical trial is to test efficacy and tolerability of combining propranolol and pembrolizumab in patients with advanced angiosarcoma or undifferentiated pleomorphic sarcoma. The main questions aims to answer: * Primary: determine the progression-free survival rate (PFSR) at 3 months Secondary: determine the objective response rate (ORR), duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS). Ensure the safety and tolerability, Determine Quality of Life (QoL) • Exploratory: Characterize the TME Participants will be asked to ensure * Baseline biopsy and further optional biopsies * Treatment propranolol 40 mg BID and pembrolizumab 2 mg/kg Q3 weeks * Evaluation, blood counts, QoL and blood samples for biomarkers according to schedule
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: cytotoxic chemotherapy — first line
who has progressed/failed to provide clinical benefit on first line standard chemotherapy
Cannot have received: anti-PD-1 therapy
Have received any previous systemic therapy targeting the PD-1/PDL-1 signaling pathway or other immune checkpoint inhibitors
Cannot have received: beta blocker (propranolol)
Have received propranolol within 4 weeks prior to treatment
Cannot have received: radiation therapy
Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and/or monoclonal antibody treatment within 4 weeks
Cannot have received: cytotoxic chemotherapy
Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and/or monoclonal antibody treatment within 4 weeks
Cannot have received: targeted small molecule therapy
Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and/or monoclonal antibody treatment within 4 weeks
Cannot have received: monoclonal antibody
Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and/or monoclonal antibody treatment within 4 weeks
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1 x 10⁹/L; Platelet count ≥ 75 x 10⁹/L
Kidney function
Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (using the Cockcroft-Gault formula)
Liver function
Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol/L); AST/ALT ≤ 5 x ULN
Patients must have normal organ and marrow function as defined below: * Absolute neutrophil count (ANC) ≥ 1 x 10⁹/L * Platelet count ≥ 75 x 10⁹/L * Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol/L) * Aspartate transaminase (AST)/Alanine transaminase (ALT) ≤ 5 x ULN * Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (using the Cockcroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify